Century Therapeutics, Inc.
IPSC
$0.51
-$0.02-3.63%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | 109.16M | 4.17M | 791.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | 109.16M | 4.17M | 791.00K |
| Cost of Revenue | 22.53M | 26.86M | 26.58M | 29.38M | 27.23M |
| Gross Profit | -22.53M | -26.86M | 82.58M | -25.20M | -26.44M |
| SG&A Expenses | 6.84M | 7.81M | 8.41M | 9.11M | 8.35M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 29.36M | 34.66M | 34.99M | 38.49M | 35.58M |
| Operating Income | -29.36M | -34.66M | 74.18M | -34.31M | -34.79M |
| Income Before Tax | -34.42M | -32.54M | 76.56M | -34.30M | -31.23M |
| Income Tax Expenses | -- | -- | -- | 1.78M | -8.00K |
| Earnings from Continuing Operations | -34.42M | -32.54M | 76.56M | -36.07M | -31.23M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -34.42M | -32.54M | 76.56M | -36.07M | -31.23M |
| EBIT | -29.36M | -34.66M | 74.18M | -34.31M | -34.79M |
| EBITDA | -26.23M | -31.46M | 77.40M | -31.00M | -31.49M |
| EPS Basic | -0.40 | -0.38 | 0.89 | -0.42 | -0.37 |
| Normalized Basic EPS | -0.20 | -0.24 | 0.56 | -0.23 | -0.23 |
| EPS Diluted | -0.40 | -0.38 | 0.89 | -0.42 | -0.37 |
| Normalized Diluted EPS | -0.20 | -0.24 | 0.56 | -0.23 | -0.23 |
| Average Basic Shares Outstanding | 86.46M | 86.24M | 86.02M | 85.41M | 84.70M |
| Average Diluted Shares Outstanding | 86.46M | 86.24M | 86.10M | 85.41M | 84.70M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |